JP2022031403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022031403A5 JP2022031403A5 JP2021209374A JP2021209374A JP2022031403A5 JP 2022031403 A5 JP2022031403 A5 JP 2022031403A5 JP 2021209374 A JP2021209374 A JP 2021209374A JP 2021209374 A JP2021209374 A JP 2021209374A JP 2022031403 A5 JP2022031403 A5 JP 2022031403A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- antigen
- antibody
- tgfβ1
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000001708 Protein Isoforms Human genes 0.000 claims 5
- 108010029485 Protein Isoforms Proteins 0.000 claims 5
- 229940124639 Selective inhibitor Drugs 0.000 claims 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000007681 cardiovascular toxicity Effects 0.000 claims 3
- 231100000060 cardiovascular toxicity Toxicity 0.000 claims 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100034A JP2023108057A (ja) | 2016-03-11 | 2023-06-19 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307353P | 2016-03-11 | 2016-03-11 | |
| US62/307,353 | 2016-03-11 | ||
| US201762443615P | 2017-01-06 | 2017-01-06 | |
| US62/443,615 | 2017-01-06 | ||
| US201762452866P | 2017-01-31 | 2017-01-31 | |
| US62/452,866 | 2017-01-31 | ||
| JP2018547346A JP2019509737A (ja) | 2016-03-11 | 2017-03-10 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| PCT/US2017/021972 WO2017156500A1 (en) | 2016-03-11 | 2017-03-10 | Tgfb1-binding immunoglobulins and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547346A Division JP2019509737A (ja) | 2016-03-11 | 2017-03-10 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100034A Division JP2023108057A (ja) | 2016-03-11 | 2023-06-19 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022031403A JP2022031403A (ja) | 2022-02-18 |
| JP2022031403A5 true JP2022031403A5 (enExample) | 2022-07-06 |
Family
ID=58503696
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547346A Withdrawn JP2019509737A (ja) | 2016-03-11 | 2017-03-10 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| JP2021174552A Withdrawn JP2022028680A (ja) | 2016-03-11 | 2021-10-26 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| JP2021209374A Pending JP2022031403A (ja) | 2016-03-11 | 2021-12-23 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| JP2023100034A Pending JP2023108057A (ja) | 2016-03-11 | 2023-06-19 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547346A Withdrawn JP2019509737A (ja) | 2016-03-11 | 2017-03-10 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| JP2021174552A Withdrawn JP2022028680A (ja) | 2016-03-11 | 2021-10-26 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100034A Pending JP2023108057A (ja) | 2016-03-11 | 2023-06-19 | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11643459B2 (enExample) |
| EP (2) | EP4169942A1 (enExample) |
| JP (4) | JP2019509737A (enExample) |
| KR (3) | KR20180122397A (enExample) |
| CN (1) | CN109071646A (enExample) |
| AU (2) | AU2017230103A1 (enExample) |
| BR (1) | BR112018068340A2 (enExample) |
| CA (1) | CA3055555A1 (enExample) |
| DK (1) | DK3365368T3 (enExample) |
| EA (1) | EA201891909A1 (enExample) |
| ES (1) | ES2951648T3 (enExample) |
| FI (1) | FI3365368T3 (enExample) |
| HU (1) | HUE062976T2 (enExample) |
| IL (2) | IL307835A (enExample) |
| MX (2) | MX2018010948A (enExample) |
| PL (1) | PL3365368T3 (enExample) |
| PT (1) | PT3365368T (enExample) |
| SG (1) | SG11201807176XA (enExample) |
| WO (1) | WO2017156500A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018010948A (es) * | 2016-03-11 | 2019-06-20 | Scholar Rock Inc | INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS. |
| CA3030862A1 (en) * | 2016-07-14 | 2018-01-18 | Scholar Rock, Inc. | Tgfb antibodies, methods, and uses |
| PE20191661A1 (es) | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
| JP2020512364A (ja) * | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
| LT3621694T (lt) | 2017-05-09 | 2023-11-27 | Scholar Rock, Inc. | Lrrc33 inhibitoriai ir jų panaudojimas |
| EP3658583A1 (en) * | 2017-07-28 | 2020-06-03 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| JP7315566B2 (ja) * | 2018-02-23 | 2023-07-26 | 中外製薬株式会社 | 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法 |
| EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
| HRP20212034T1 (hr) | 2018-07-11 | 2022-04-01 | Scholar Rock, Inc. | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe |
| MA53125A (fr) * | 2018-07-11 | 2021-05-19 | Scholar Rock Inc | Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée |
| TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
| EP3877055A1 (en) * | 2018-11-05 | 2021-09-15 | Ludwig Institute for Cancer Research Ltd | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
| MX2021009175A (es) * | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
| EP3929215A4 (en) * | 2019-06-10 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE |
| KR20250093432A (ko) * | 2019-08-28 | 2025-06-24 | 추가이 세이야쿠 가부시키가이샤 | 종교차성 항잠재형 TGF-β1 항체 및 사용 방법 |
| WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
| TW202135862A (zh) * | 2020-01-11 | 2021-10-01 | 美商供石公司 | TGFβ抑制劑及其用途 |
| CN115335393A (zh) * | 2020-03-24 | 2022-11-11 | 博奥泰克尼公司 | 使用TGFβ敲除细胞系及由其产生的组合物的方法 |
| BR112023014319A2 (pt) * | 2021-01-18 | 2023-09-26 | Jiangxi Jemincare Group Co Ltd | Anticorpo contra a proteína garp e aplicação do mesmo |
| WO2022180764A1 (en) | 2021-02-26 | 2022-09-01 | Chugai Seiyaku Kabushiki Kaisha | Uses of cross-species anti-latent tgf-beta 1 antibodies |
| JP7280400B2 (ja) * | 2021-02-26 | 2023-05-23 | 中外製薬株式会社 | 種交差性抗潜在型ＴＧＦ－β１抗体の使用 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022206753A1 (zh) * | 2021-03-29 | 2022-10-06 | 山东先声生物制药有限公司 | GARP/TGFβ1抗体及其应用 |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| US20230346934A1 (en) | 2022-03-29 | 2023-11-02 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
| GB202219154D0 (en) * | 2022-12-19 | 2023-02-01 | Metacurum Biotech Ab | Antibodies and uses thereof |
| KR20250133913A (ko) * | 2023-01-09 | 2025-09-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도 |
| EP4662245A1 (en) | 2023-02-10 | 2025-12-17 | Chugai Seiyaku Kabushiki Kaisha | Anti-latent tgf-beta 1 antibodies and methods of use |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| CN120131938B (zh) * | 2025-03-19 | 2025-12-23 | 广州奥奇生物技术有限公司 | 一种益生菌制剂的制备方法及其在改善睡眠中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5262319A (en) | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| WO1997035991A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| IL153567A0 (en) | 2000-06-29 | 2003-07-06 | Abbott Lab | Dual specificity antibodies and methods of making and using |
| GB0230202D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
| JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | ＴＧＦ−β活性化制御領域の切断面を認識する抗体 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| MX2007009545A (es) | 2005-02-08 | 2008-03-11 | Genzyme Corp | Anticuerpos para tgfbeta. |
| EA016038B1 (ru) | 2005-04-22 | 2012-01-30 | Эли Лилли Энд Компани | Антитело к tgf-бета и его применение |
| HUE041818T2 (hu) | 2007-03-22 | 2019-05-28 | Biogen Ma Inc | Kötõ proteinek, beleértve az antitesteket, CD154-et specifikusan kötõ antitest származékokat és antitest fragmenseket is, és alkalmazásaik |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
| UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| MX341578B (es) | 2011-02-08 | 2016-08-25 | Abbvie Inc | Tratamiento de la osteoartritis y del dolor. |
| AU2012260601B2 (en) | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
| HRP20211582T1 (hr) | 2011-06-03 | 2022-01-07 | Xoma Technology Ltd. | Protutijela specifična za tgf-beta |
| RU2708977C2 (ru) | 2011-06-10 | 2019-12-12 | МЕДИММЬЮН, ЭлЭлСи | Молекулы, связывающиеся с psl pseudomonas, и пути их применения |
| EP3653222A1 (en) | 2011-10-14 | 2020-05-20 | Novartis AG | Antibodies and methods for wnt pathway-related diseases |
| BR112014011115A2 (pt) | 2011-11-08 | 2017-06-13 | Pfizer | métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf |
| EP2780368B1 (en) | 2011-11-14 | 2018-01-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| EP2822592B1 (en) | 2012-03-08 | 2018-08-15 | Ludwig Institute for Cancer Research Limited | Tgf- 1 specific antibodies and methods and uses thereof |
| MX388059B (es) | 2012-11-06 | 2025-03-19 | Scholar Rock Inc | Composiciones y metodos para modular la comunicacion celular. |
| EP2968548B1 (en) | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| NZ717476A (en) | 2013-08-01 | 2022-04-29 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| US20170073406A1 (en) | 2014-05-06 | 2017-03-16 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| RU2703903C2 (ru) | 2014-06-26 | 2019-10-22 | Хайдельберг Иммунотерапьютикс Гмбх | Местное применение антитела к hsv |
| EP3221348B1 (en) | 2014-11-18 | 2020-12-09 | Institut Pasteur | Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis |
| AU2016206682B2 (en) | 2015-01-14 | 2021-11-11 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-LAP monoclonal antibodies |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| MX2018010948A (es) * | 2016-03-11 | 2019-06-20 | Scholar Rock Inc | INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS. |
| CA3030862A1 (en) | 2016-07-14 | 2018-01-18 | Scholar Rock, Inc. | Tgfb antibodies, methods, and uses |
| PE20191661A1 (es) | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
-
2017
- 2017-03-10 MX MX2018010948A patent/MX2018010948A/es unknown
- 2017-03-10 CN CN201780023887.8A patent/CN109071646A/zh active Pending
- 2017-03-10 BR BR112018068340A patent/BR112018068340A2/pt unknown
- 2017-03-10 KR KR1020187028835A patent/KR20180122397A/ko not_active Ceased
- 2017-03-10 FI FIEP17716332.6T patent/FI3365368T3/fi active
- 2017-03-10 CA CA3055555A patent/CA3055555A1/en active Pending
- 2017-03-10 KR KR1020257001174A patent/KR20250011248A/ko active Pending
- 2017-03-10 WO PCT/US2017/021972 patent/WO2017156500A1/en not_active Ceased
- 2017-03-10 ES ES17716332T patent/ES2951648T3/es active Active
- 2017-03-10 IL IL307835A patent/IL307835A/en unknown
- 2017-03-10 SG SG11201807176XA patent/SG11201807176XA/en unknown
- 2017-03-10 EP EP22195559.4A patent/EP4169942A1/en active Pending
- 2017-03-10 EA EA201891909A patent/EA201891909A1/ru unknown
- 2017-03-10 US US16/083,637 patent/US11643459B2/en active Active
- 2017-03-10 PL PL17716332.6T patent/PL3365368T3/pl unknown
- 2017-03-10 DK DK17716332.6T patent/DK3365368T3/da active
- 2017-03-10 HU HUE17716332A patent/HUE062976T2/hu unknown
- 2017-03-10 JP JP2018547346A patent/JP2019509737A/ja not_active Withdrawn
- 2017-03-10 PT PT177163326T patent/PT3365368T/pt unknown
- 2017-03-10 AU AU2017230103A patent/AU2017230103A1/en not_active Abandoned
- 2017-03-10 KR KR1020237018780A patent/KR20230088508A/ko not_active Ceased
- 2017-03-10 EP EP17716332.6A patent/EP3365368B1/en active Active
-
2018
- 2018-08-29 IL IL261442A patent/IL261442A/en unknown
- 2018-09-10 MX MX2024005811A patent/MX2024005811A/es unknown
-
2021
- 2021-10-26 JP JP2021174552A patent/JP2022028680A/ja not_active Withdrawn
- 2021-12-23 JP JP2021209374A patent/JP2022031403A/ja active Pending
-
2023
- 2023-03-31 US US18/193,979 patent/US20230348583A1/en active Pending
- 2023-06-19 JP JP2023100034A patent/JP2023108057A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202692A patent/AU2024202692A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031403A5 (enExample) | ||
| JP2019509737A5 (enExample) | ||
| FI3365368T3 (fi) | Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö | |
| JP2017039771A5 (enExample) | ||
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| JP2022188083A5 (enExample) | ||
| JP2019529476A5 (enExample) | ||
| Gordon-Taylor | The incomputable factor in cancer prognosis | |
| JP2015517523A5 (enExample) | ||
| CN109069469A (zh) | 治疗癌症的方法 | |
| JP2021105005A5 (enExample) | ||
| Frankenthaler et al. | Fibrosarcoma of the head and neck | |
| JPWO2020037091A5 (enExample) | ||
| JPWO2020037092A5 (enExample) | ||
| JP2019519573A (ja) | がんを処置するための方法 | |
| Goldman et al. | Late recurrence of squamous cell cervical cancer in an episiotomy site after vaginal delivery | |
| Glaser et al. | Complications of intracavitary brachytherapy for gynecologic cancers and their management: a comprehensive review | |
| Triantafillidou et al. | Epithelioid angiosarcoma of the maxillary sinus and the maxilla: a case report and review of the literature | |
| Freiberger et al. | Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer | |
| JP2020521786A5 (enExample) | ||
| JPWO2020051356A5 (enExample) | ||
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| Milsted et al. | A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer | |
| Saneesh et al. | CT of primary undifferentiated pleomorphic sarcoma of small intestine with distant metastases presenting with intussusception | |
| CN110115767A (zh) | 免疫调节剂联合检查点抑制剂治疗癌症的方法 |